BMS to Acquire MyoKardia
We announced our agreement to acquire MyoKardia, whose portfolio of pipeline drug candidates includes mavacamten, a potential first-in-class medicine that shows compelling data in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Click here for an overview.
Global Patient Week
Our week-long patient celebration allows us to reconnect with our mission, celebrate and honor the patients we have helped, strive to do more for the patients who do not yet have an answer and share our inspiration and motivation with the world.
A subset of BMS.com, Life & Science Stories is where we share the work our global community of colleagues are doing around the world to help patients and advance scientific innovation.
Looking for Answers?
Quick links to helpful resources.